CircPIAS1-108aa and application of circPIAS1-108aa inhibitor in preparation of antitumor drugs
By developing inhibitors of circPIAS1-108aa, the problem of poor efficacy of cancer treatment in the existing technology was solved. Targeted technology inhibited circPIAS1-108aa significantly inhibited cancer cell growth and enhanced the efficacy of immune drugs, providing a new cancer treatment strategy .
Patent Information
- Application Number
- CN202411246545.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-06
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2044-09-06
AI Technical Summary
Existing cancer treatment methods, especially immune checkpoint inhibitors, have poor efficacy, and the regulatory mechanism of circRNA in cancer has not been fully understood. In particular, the function of circPIAS1 has not been reported in the literature, and there is a lack of effective target protein inhibitors.
Develop inhibitors of the target protein circPIAS1-108aa, which inhibits the expression or activity of circPIAS1-108aa through siRNA, ASOs, antibodies and blockers, and is used to prepare anti-tumor drugs and combine them with immune drugs to enhance their efficacy.
It significantly inhibits the growth of cancer cells and significantly improves the anti-tumor efficacy of immune drugs. It has an inhibitory effect on a variety of common cancers such as lung cancer, liver cancer, gastric cancer, etc., and enhances the effect of immunotherapy.
Smart Images

Figure CN118976111A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to cancer, and in particular to application of circPIAS1-108aa and an inhibitor thereof in the preparation of anti-tumor drugs. Technical Background
[0002] Cancer, also known as malignant tumor, is caused by malignant cell proliferation, most of which are invasive and metastatic. Cancer is diverse and has a complex pathogenesis. It has become the most important factor endangering the lives and health of people in my country. Common types of cancer in clinical research in my country include lung cancer, liver cancer, gastric cancer, melanoma, pancreatic cancer, breast cancer, nasopharyngeal cancer, colorectal cancer, esophageal cancer, prostate cancer, etc. These cancers develop rapidly and are difficult to control with conventional chemotherapy. Therefore, immune checkpoint inhibitors are often used for targeted therapy, but the actual effect is still poor.
[0003] Circular non-coding RNAs (circRNAs) are a type of regulatory non-coding RNA, which is formed by reverse shearing of pre-mRNA. They have a circular covalently closed structure and can withstand degradation by RNA enzymes, providing a guarantee for their stable function in the body. CircRNA plays many important roles in the occurrence and development of diseases, especially in the field of cancer. For example, hsa_circ_102481 is highly expressed in non-small cell lung cancer with EGFR-TKI resistance. It can adsorb miR-30a-50p through a molecular sponge mechanism, adjust ROR1 levels, and promote tumor proliferation and metastasis.
[0004] As a circRNA, the function of circPIAS1 has not been reported in the literature. Summary of the invention
[0005] Purpose of the invention: To solve the above problems, the present invention provides the application of target protein circPIAS1-108aa inhibitor in treating cancer and enhancing the efficacy of immune drugs, providing a basis for the development of drugs for treating cancer.
[0006] Technical solution: In order to achieve the above-mentioned invention object, the technical solution of the present invention is as follows:
[0007] The use of circPIAS1-108aa as a target in the development, screening or preparation of drugs for preventing or treating tumors is characterized in that the amino acid sequence of circPIAS1-108aa is SEQ ID NO.1.
[0008] The use of the circPIAS1-108aa inhibitor in the preparation of anti-tumor drugs.
[0009] The application is characterized in that the circPIAS1-108aa inhibitor is a substance that inhibits the activity or expression of circPIAS1-108aa.
[0010] The application is characterized in that the circPIAS1-108aa inhibitor includes small molecule organic matter, small molecule inorganic matter, anti-circPIAS1-108aa antibody, a nucleic acid fragment or a polypeptide that can specifically bind to circPIAS1-108aa and inhibit its activity.
[0011] The application is characterized in that the circPIAS1-108aa inhibitor is selected from artificially synthesized small interfering RNA siRNA or antisense oligonucleotides ASOs.
[0012] The application is characterized in that the tumor includes lung cancer, liver cancer, gastric cancer, melanoma, pancreatic cancer, breast cancer, nasopharyngeal cancer, colorectal cancer, esophageal cancer or prostate cancer.
[0013] A use of a pharmaceutical composition in the preparation of an anti-tumor drug, characterized in that the pharmaceutical composition comprises the circPIAS1-108aa inhibitor.
[0014] The application is characterized in that the pharmaceutical composition comprises a circPIAS1-108aa inhibitor and a pharmaceutically acceptable carrier.
[0015] Specifically:
[0016] The present invention first discovered that the cancer-promoting factor circPIAS1-108aa can be used as a cancer treatment target. Therefore, substances that inhibit this target can be used to treat cancer. The target circPIAS1-108aad inhibitor of the present invention is a substance that inhibits the activity or expression of circPIAS1-108aa.
[0017] The target circPIAS1-108aa d inhibitor of the present invention can inhibit the expression of circPIAS1-108aa protein or inhibit its activity / function by the following means, thereby being used to prevent and / or treat cancer:
[0018] siRNA and / or ASOs targeting circPIAS1 to promote its degradation;
[0019] Knockout circPIAS1 by gene knockout technology;
[0020] Blockers, antagonists or inhibitors that target circPIAS1-108aa protein and inhibit its function;
[0021] Inhibitors that inhibit the expression of circPIAS1 gene or protein;
[0022] Neutralizing antibodies, blocking antibodies or blocking peptides of CircPIAS1-108aa are not limited to the above methods.
[0023] As a further option:
[0024] The target protein circPIAS1-108aa inhibitor includes but is not limited to small molecule organic matter, small molecule inorganic matter, anti-circPIAS1-108aa antibody, nucleic acid fragment or polypeptide that can specifically bind to circPIAS1-108aa and inhibit its activity.
[0025] The target protein circPIAS1-108aa inhibitor also includes an inhibitor precursor.
[0026] For example, the circPIAS1-108aa inhibitor can be selected from artificially synthesized small interfering ribonucleic acid (siRNA) or antisense oligonucleotides (ASOs).
[0027] The cancer includes all kinds of cancer, such as lung cancer, liver cancer, gastric cancer, melanoma, pancreatic cancer, breast cancer, nasopharyngeal cancer, colorectal cancer, esophageal cancer, prostate cancer, etc.
[0028] The target protein circPIAS1-108aa inhibitor can inhibit the growth of cancer and enhance the efficacy of immune drugs, thereby preventing, improving or treating cancer.
[0029] Beneficial Effects
[0030] The latest research shows that even though circRNA is defined as non-coding RNA, a small number of them still have the ability to encode proteins, and the peptides encoded by them have also been confirmed to be key factors affecting tumor progression. Some studies have found that Circ-E-cadherin can promote the progression of glioma, but interestingly, it does not work through the miRNA molecular sponge mechanism, but through multiple rounds of translation by the ribosome to produce a 254 amino acid long polypeptide to bind to the CR2 domain of EGFR, thereby reactivating the EGFR downstream pathway and limiting the effectiveness of EGFR inhibitors. circPIAS1 is also one of the few non-coding RNAs that has the ability to encode proteins.
[0031] As a circRNA, circPIAS1 has no function reported in the literature. The present invention unexpectedly found that circPIAS1 itself has no effect on promoting tumor proliferation, but the polypeptide circPIAS1-108aa expressed by it is a cancer-promoting factor, which is a new target protein with a length of 108 amino acids encoded by circPIAS1. There is no report on inhibiting circPIAS1-108aa to treat cancer.
[0032] Specifically:
[0033] (1) circPIAS1-108aa is a key factor in promoting cancer progression. LC-MS / MS technology was used to identify the existence and sequence correctness of a special protein (circPIAS1-108aa) encoded by circPIAS1 with a length of 108 amino acids. By constructing wild-type and ATG mutant overexpression plasmids and verifying through cloning experiments that circPIAS1's cancer-promoting effect depends on circPIAS1-108aa. The key is to design siRNA or ASOs targeted inhibitors based on the looping site of circPIAS1 to specifically downregulate the level of circPIAS1, thereby significantly inhibiting cancer cell growth.
[0034] The targeting sequence of ASOs is any of the following:
[0035] #1:5'-GCAGAAATTGGAAGACATC-3', SEQ ID NO.2
[0036] #2:5'-ATTGGAAGACATCAGACAA-3', SEQ ID NO.,3
[0037] #3:5'-GAAGACATCAGACAACAGT-3', SEQ ID NO.,4
[0038] #4:5'-GACTGCAGAAATTGGAAGAC-3', SEQ ID NO.,5
[0039] #5: 5'-AGACATCAGACAACAGTCAG-3', SEQ ID NO., 6.
[0040] (2) The use of inhibitors targeting circPIAS1-108aa can significantly enhance the anti-tumor efficacy of immune drugs. Animal in vivo experiments have verified that downregulating circPIAS1-108aa levels while administering immune drugs significantly enhances the anti-tumor effect compared to administering immune drugs alone.
[0041] This application discovered the application of inhibitors of the target circPIAS1-108aa in cancer treatment through experiments. The inhibitor plays an inhibitory role in the proliferation of ten common cancers, including lung cancer, liver cancer, gastric cancer, melanoma, pancreatic cancer, breast cancer, nasopharyngeal cancer, colorectal cancer, esophageal cancer, and prostate cancer; and the inhibitor of the target circPIAS1-108aa can significantly enhance the efficacy of immune checkpoint inhibitors, providing a new synergistic strategy for tumor immunotherapy. BRIEF DESCRIPTION OF THE DRAWINGS
[0042] Figure 1 Verification results of circPIAS1 encoding circPIAS1-108aa, where a is the protein sequence encoded by circPIAS1 predicted by circPrimer2.0, and b is the mass spectrometry detection of circPIAS1-108aa, showing that the target circPIAS1-108aa actually exists in tumor cells and is consistent with the predicted amino acid sequence.
[0043] Figure 2 The results of screening circPIAS1-108aa as a cancer-promoting factor and drug target, where a is the result of the clone formation experiment, and b is the relative quantification, showing that the cancer-promoting effect of the target circPIAS1 mainly depends on the novel protein circPIAS1-108aa it encodes, rather than the function at the RNA level.
[0044] Figure 3 These are the in vitro efficacy results of the inhibitor of circPIAS1-108aa, where: a is the result of the clone formation experiment, and b is the relative quantitative statistical result, showing the changes in the proliferation ability of tumor cells after downregulating circPIAS1 by ASOs inhibitors.
[0045] Figure 4 The in vivo efficacy results of the inhibitor of circPIAS1-108aa, where: a is a schematic diagram of the in vivo animal experimental method, b is the weight change of mice after different treatments, c is the tumor tissue of different treatment groups, and d is the relative quantification of the size of tumor tissue in different groups, showing that the inhibitor of the target circPIAS1-108aa can significantly enhance the inhibitory effect of immune drugs on tumors without affecting the normal growth of mice; *P<0.05, **P<0.01. DETAILED DESCRIPTION
[0046] The present application is described in detail below in conjunction with specific embodiments.
[0047] The H1975 (lung cancer), HepG2 (liver cancer), SGC-7901 (gastric cancer), A375 (melanoma), AsPC-1 (pancreatic cancer), T-47D (breast cancer), CNE-1 (nasopharyngeal cancer), HCT-116 (colorectal cancer), SKGT-4 (esophageal cancer), and Du 145 (prostate cancer) cell lines used in the examples were kindly provided by the Chinese Academy of Sciences Stem Cell Bank (Shanghai, China). The amino acid sequence of the target protein circPIAS1-108aa used in the study was predicted by circPrimer2.0 and verified by LC-MS / MS. The ASOs used in the experiment were designed by our research group and commissioned to be synthesized by Guangzhou Ruibo Biotechnology Co., Ltd.
[0048] Example 1 circPIAS1 was confirmed to encode a novel target protein of 108 amino acids
[0049] According to the prediction of circPrimer2.0 software, circPIAS1 (ID: hsa_circ_0008378) can encode a special polypeptide with a length of 108 amino acids. The protein sequence is:
[0050] MDISGTKCDFTVQVQLRFCLSETSCPQEDHFPPNLCVKVNTKPCSLPGYLPPTKNGVEPKRPSRPINITSLVRLSTTVPNTIVVSWTAEIGRLQTTASAFGKPVLHLP, see SEQ ID NO.1.
[0051] LC-MS / MS technology successfully verified the existence of circPIAS1-108aa.
[0052] The results are as follows Figure 1 As shown, circPIAS1-108aa actually exists in tumor cells and is consistent with the predicted amino acid sequence.
[0053] Example 2 circPIAS1-108aa is a key cancer-promoting factor and drug target
[0054] In the cloning experiment, ten tumor cells were inoculated into 6-well plates at a density of 2×103 cells per well. After 8 hours of transfection of three overexpression plasmids, Vector (empty), circPIAS1-108aa (overexpression at RNA and protein levels), and circPIAS1-ATG-mut (overexpression at RNA level only), the culture medium was replaced with fresh culture medium and cultured for another 7 days. Finally, the cell colonies were stained with crystal violet.
[0055] The results are as follows Figure 2As shown, this indicates that the cancer-promoting effect of circPIAS1 mainly depends on the novel protein it encodes rather than the function at the RNA level. It also proves that circPIAS1-108aa has a high target potential.
[0056] Example 3 The proliferation ability of tumor cells was significantly inhibited after using the specific inhibitor of circPIAS1-108aa
[0057] In the clone formation experiment, 2 × 10 3 Ten types of tumor cells were inoculated into 6-well plates at a density of 10 cells. After transfection with circPIAS1-108aa inhibitor ASOs for 8 hours, the culture medium was replaced with fresh culture medium and cultured for another 7 days. Finally, the cell colonies were stained with crystal violet.
[0058] The results are as follows Figure 3 As shown in the figure, after downregulating circPIAS1 by ASOs, the number of tumor cell clones was significantly reduced, indicating that the inhibitor of circPIAS1 can significantly inhibit tumor growth.
[0059] Example 4 Target protein circPIAS1-108aa inhibitor can significantly enhance the anti-tumor effect of immune drugs
[0060] In this experiment, 6-8 week-old C57BL / 6J male and female mice (SPF) were used as research subjects. 2×10 5 When the tumor of C57 mice grew to 50 mm 3 , divided into four groups for drug treatment, and this date was recorded as day 0. PD-1 inhibitors and IgG negative controls were given once every 3 days starting from day 0, with 2 mg / kg injected intraperitoneally each time, for a total of five times. ASO-circPIAS1 and ASO-NC were used to specifically inhibit circPIAS1-108aa, starting from day 3, once every 3 days, with 10 nmol injected intratumorally each time, for a total of four times. During this period, the weight and tumor volume of the mice were observed and recorded, and finally the tumor tissues of each group were collected on day 14 for analysis.
[0061] The results are as follows Figure 4 As shown, the use of inhibitors targeting circPIAS1-108aa can significantly enhance the inhibitory effect of immune drugs on tumors.
Claims
1. Use of circPIAS1-108aa as a target in the development, screening or preparation of drugs for the prevention or treatment of tumors, characterized in that: The amino acid sequence of circPIAS1-108aa is SEQ ID NO.
1.
2. Use of the inhibitor of circPIAS1-108aa according to claim 1 in the preparation of anti-tumor drugs.
3. The use according to claim 2, characterized in that: The circPIAS1-108aa inhibitor is a substance that inhibits the activity or expression of circPIAS1-108aa.
4. The use according to claim 3, characterized in that: The circPIAS1-108aa inhibitor includes small molecule organic matter, small molecule inorganic matter, anti-circPIAS1-108aa antibody, and a nucleic acid fragment or polypeptide that can specifically bind to circPIAS1-108aa and inhibit its activity.
5. The use according to claim 4, characterized in that: The circPIAS1-108aa inhibitor is selected from artificially synthesized small interfering RNA siRNA or antisense oligonucleotides ASOs.
6. The use according to claim 5, characterized in that: The antisense oligonucleotide ASOs is any one of the following nucleotide sequences: #1:5'-GCAGAAATTGGAAGACATC-3', SEQ ID NO.2 #2:5'-ATTGGAAGACATCAGACAA-3', SEQ ID NO.,3 #3:5'-GAAGACATCAGACAACAGT-3', SEQ ID NO.,4 #4:5'-GACTGCAGAAATTGGAAGAC-3', SEQ ID NO.,5 #5: 5'-AGACATCAGACAACAGTCAG-3', SEQ ID NO., 6.
7. The use according to claim 1, characterized in that: The tumor includes lung cancer, liver cancer, gastric cancer, melanoma, pancreatic cancer, breast cancer, nasopharyngeal cancer, colorectal cancer, esophageal cancer or prostate cancer.
8. Use of a pharmaceutical composition in the preparation of an anti-tumor drug, characterized in that: The pharmaceutical composition comprises the circPIAS1-108aa inhibitor according to any one of claims 2-5.
9. The use according to claim 7, characterized in that: The pharmaceutical composition includes a circPIAS1-108aa inhibitor and a pharmaceutically acceptable carrier.
Citation Information
Patent Citations
Application of CircPIAS1 as target spot in preparation of liver cancer diagnostic reagent or therapeutic drug
CN115501340A
Tumor immunotherapy prognosis evaluation preparation and application of ANO1-targeting reagent in preparation of medicine for improving tumor prognosis
CN116926193A
Application of novel immune checkpoint PIEZO1 pathway in tumor T cell therapy
CN117653733A
Polypeptide and application thereof
WO2018090257A1
